ADCs

Analysis Method for Drug-to-Antibody Ratio (DAR) of Antibody-drug Conjugates

Analysis Method for Drug-to-Antibody Ratio (DAR) of Antibody-drug Conjugates

The Drug-to-Antibody Ratio (DAR) is the most important quality attribute of ADC drugs because it determines the “payload” that can be delivered to tumors, directly impacting safety and efficacy. Here, we […]

Comparison and Analysis of SMDC, ADC, and DAC

Comparison and Analysis of SMDC, ADC, and DAC

In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the […]

ADCs

Several Ways of Thiol Coupling in ADCs

The popularity of thiol coupling in ADC preparation can be attributed to three factors: It is essential to note that a reduction step is always required before coupling to release […]

lab research

Emerging ADC Targets: B7-H3 and B7-H4

B7-H3 and B7-H4 are type I transmembrane proteins belonging to the B7 family. Their abnormal expression is associated with many diseases such as colon cancer, breast cancer, liver cancer, and […]

drugs

List of ADCs Targeting HER

Introduction to HER and ADCs Members of the human epidermal growth factor receptor (HER) family, including HER1 (EGFR), HER2, HER3, and HER4, play a core role in regulating cell proliferation, […]

linker design

Linker Design Impacts Drug Conjugate Pharmacokinetics and Efficacy

In recent years, antibody-drug conjugates (ADCs) have achieved substantial success in cancer therapy. Typically, an antibody or peptide in a conjugated drug acts as a precisely located “navigator” while a small-molecule […]

ADCs Make Their Mark in HER-Positive Cancers

ADCs Make Their Mark in HER-Positive Cancers

Members of the human epidermal growth factor receptor (HER) family, including HER1 (EGFR), HER2, HER3, and HER4, play central roles in regulating cell proliferation, survival, differentiation, and migration. Overexpression of […]